3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
lutetium Lu 177 dotatate
16
Magnetic Resonance Spectroscopy
14
gallium Ga 68 dotatate
9
Specimen Handling
8
Everolimus
8
pembrolizumab
7
cabozantinib
6
Cisplatin
6
fluorodopa F 18
5
Etoposide
5
trametinib
4
surufatinib
4
lanreotide
4
dabrafenib
4
cemiplimab
4
X-Rays
4
Temozolomide
4
Nivolumab
4
Lutetium-177
4
Lutetium
4
Fluorodeoxyglucose F18
4
Carboplatin
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
olaparib
3
lenvatinib
3
copper dotatate CU-64
3
Transurethral Resection of Prostate
3
Thyrotropin Alfa
3
Surveys and Questionnaires
3
Somatostatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
gadoterate meglumine
×
Endocrine
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled